Trials / Completed
CompletedNCT00490685
Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Randomized Continuation, Dose Escalation Trial of Sorafenib in Patients With Advanced HCC With Radiological Progression on Prior Sorafenib Treatment (Phase II Study)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 142 (actual)
- Sponsor
- Istituto Clinico Humanitas · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to evaluate, after radiological progression, efficacy in patients treated with Sorafenib at a dose of 600 mg bid compared to that in patients treated with best supportive care. Primary efficacy objective is progression free survival from randomization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (BAY-43-9006) |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2008-06-01
- First posted
- 2007-06-25
- Last updated
- 2010-09-02
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT00490685. Inclusion in this directory is not an endorsement.